Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Net Income towards Common Stockholders (2020 - 2025)

Oncology Institute's Net Income towards Common Stockholders history spans 6 years, with the latest figure at -$6.4 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 40.63% year-over-year to -$6.4 million; the TTM value through Dec 2025 reached -$53.8 million, up 5.02%, while the annual FY2025 figure was -$50.3 million, 5.09% up from the prior year.
  • Net Income towards Common Stockholders reached -$6.4 million in Q4 2025 per TOI's latest filing, up from -$13.8 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $19.3 million in Q1 2022 to a low of -$30.0 million in Q1 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$10.2 million, with a median of -$11.8 million recorded in 2022.
  • Peak YoY movement for Net Income towards Common Stockholders: plummeted 248350400.0% in 2021, then surged 238.35% in 2022.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$9.9 million in 2021, then fell by 10.8% to -$11.0 million in 2022, then plummeted by 70.38% to -$18.8 million in 2023, then soared by 42.27% to -$10.8 million in 2024, then surged by 40.63% to -$6.4 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Net Income towards Common Stockholders are -$6.4 million (Q4 2025), -$13.8 million (Q3 2025), and -$14.0 million (Q2 2025).